European stocks mixed; strong AstraZeneca numbers help U.K. outperform
AstraZeneca stock rose 3.5% after the drugmaker delivered
better-than-expected profits and sales in the second quarter as a strong
performance of its blockbuster cancer drugs helped offset the loss of
COVID-19 vaccine sales.
All comments
Comment not found